Saquon Barkley Partners with Wawa in a New Commercial to Celebrate Fans

Saquon Barkley Partners with Wawa in a New Commercial to Celebrate Fans Wawa and the Philadelphia Eagles' running back collaborated to announce a brand-new hoagie, “The Saquon,” just in time for football season GlobeNewswire September 02, 2025 WAWA, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) — Saquon Barkley, the world championship-winning running back for the Philadelphia […]

Interview Assesses How Trump Plans to Restore America’s “Birthright”

Interview Assesses How Trump Plans to Restore America's “Birthright” Interview Uncovers Strategy to Break China's Grip and Rebuild U.S. Industry GlobeNewswire September 02, 2025 Washington, D.C., Sept. 02, 2025 (GLOBE NEWSWIRE) — An interview with economist and former CIA advisor Jim Rickards reveals how the United States could soon reclaim control of its own resources

Baker Hughes Selected by Fervo Energy to Deliver Geothermal Power Generation Equipment for Innovative New Power Plants

Baker Hughes Selected by Fervo Energy to Deliver Geothermal Power Generation Equipment for Innovative New Power Plants GlobeNewswire September 02, 2025 Baker Hughes to design and deliver key equipment for geothermal Organic Rankine Cycle (ORC) power plants at Fervo's Cape Station Phase II project in Utah Award includes Baker Hughes turboexpander, BRUSH(TM) Power Generation generator

Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy

Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy GlobeNewswire September 02, 2025 Selective APRIL inhibition has shown disease-modifying potential in IgAN patient clinical trials JADE101 has shown ultra-high binding affinity and a

Apollo to Proceed with 5-for-1 Share Consolidation

Apollo to Proceed with 5-for-1 Share Consolidation GlobeNewswire September 02, 2025 VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) — Apollo Silver Corp. (“Apollo” or the “Company“) (TSX.V:APGO, OTCQB:APGOF, Frankfurt:6ZF0) is pleased to announce that, further to the Company's news release dated October 3, 2024, it intends to proceed with the consolidation (the “Consolidation“) of

Playboy to Participate in Lake Street’s Best Ideas Growth Conference

Playboy to Participate in Lake Street's Best Ideas Growth Conference GlobeNewswire September 02, 2025 LOS ANGELES, Sept. 02, 2025 (GLOBE NEWSWIRE) — Playboy, Inc. (Nasdaq: PLBY) (the “Company” or “Playboy”), one of the most recognizable and iconic brands in the world, announced today that management will participate in the 9th Annual Lake Street Capital Markets

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate GlobeNewswire September 02, 2025 EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into second quarter of 2027 Company-sponsored webinar on EDIT-401

Fury Announces Results of Preliminary Economic Assessment for the Eau Claire Gold Deposit with a Base Case After-Tax NPV (5%) of $554M and After-Tax IRR of 41%

Fury Announces Results of Preliminary Economic Assessment for the Eau Claire Gold Deposit with a Base Case After-Tax NPV (5%) of $554M and After-Tax IRR of 41% GlobeNewswire September 02, 2025 TORONTO, Sept. 02, 2025 (GLOBE NEWSWIRE) — Fury Gold Mines Limited (TSX and NYSE American: FURY) (“Fury” or the “Company”) is pleased to announce

Neumora Therapeutics to Participate in Upcoming Conferences in September

Neumora Therapeutics to Participate in Upcoming Conferences in September GlobeNewswire September 02, 2025 WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that

Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer

Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer GlobeNewswire September 02, 2025 Study to explore the palazestrant-atirmociclib combination in approximately 35 patients with initiation anticipated in H2 2025 Results to inform potential pivotal Phase 3 trial of novel combination in frontline metastatic breast cancer

Scroll to Top